Renibus Therapeutics initiates long-term study of Veverimer for CKD and metabolic acidosis
Renibus Therapeutics is conducting a 264-week study to assess the efficacy and safety of Veverimer in adults with moderate-to-severe CKD and metabolic acidosis.